Cold-chain medicines: how temperature-sensitive drugs travel safely

Creator: Reserve Meds
Published: 2026-10-17

What WHO's good storage and distribution practices require, and the questions to ask before a shipment leaves.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Sources accessed 17 October 2026.

The short answer

Many specialty medicines, such as biologics and some injectables, must stay within a set temperature range from the factory to the patient. Under WHO's good storage and distribution practices, they travel under the conditions on their label, with temperature monitored and recorded by calibrated instruments, data reviewed on receipt, and any deviation reported. A broken cold chain can make a medicine unusable.

Standard: WHO TRS 1025, Annex 7: good storage and distribution practices (2020).
Rule of thumb: Follow the storage conditions on the label, all the way.
Proof: A temperature record for the whole journey.
If it goes wrong: Report the deviation; do not use the product until it is assessed.

What 'cold chain' means

WHO notes that medical products face risks at every stage of the supply chain, including purchasing, storage, repackaging, relabelling, transportation and distribution, and that different people and organizations handle them along the way. Its good storage and distribution practices set out how to protect quality at each step.^[1]

For a temperature-sensitive medicine, the cold chain is the unbroken series of refrigerated or frozen storage and transport steps that keeps it within its labelled range.

What WHO's good practices require in transit

Medicines travel under the conditions stated on their label, using a cold chain for temperature-sensitive products.^{[2, 1]}
Conditions are monitored and recorded with calibrated instruments.^{[2, 1]}
Shipping containers must not harm product quality.^{[2, 1]}
Transport temperature data are reviewed when the shipment is received.^{[2, 1]}
Any temperature deviation in transit is reported to the supplier, distributor and recipient.^{[2, 1]}

What families and hospitals should ask before a shipment

What temperature range does the US label require, and is the product refrigerated, frozen or room temperature?
What validated shipper is used, and how long is it qualified to hold temperature?
Is a data logger included, and who downloads and reviews the record on arrival?
Who receives the shipment, and is a refrigerator or freezer ready before it lands?
What happens if customs holds the parcel: who is contacted, and how long can the shipper hold?

Customs delays are the most common risk. A complete set of import documents, ready before the shipment leaves, is the best protection.

Cold chain and import rules in the Gulf

Bahrain's rules for hospital imports of non-registered medicines require transport and storage in containers that meet the manufacturer's recommended conditions, and outer packs labelled with storage conditions, batch number and expiry date.^[3]

Saudi Arabia's personal-use clearance excludes vaccines and medicines that need medical supervision, which covers many cold-chain injectables. Those need a hospital route such as the SFDA Special Access Program.^{[4, 5]}

Gene and cell therapies are a special case

Many cell and gene therapies are shipped frozen under very tight controls and are given only at qualified treatment centers. The manufacturer and the center manage that logistics chain, which is one reason these therapies are usually given where the center is.^[6]

Cold chain and the documents customs will ask for

Delays at the border are where temperature excursions often happen. Bahrain's rules for hospital imports require outer packs to show the trade name, scientific name, strength, storage conditions, batch number, dosage form, production and expiry dates, and the manufacturer's name and address.^[3]

For personal-use clearance in Saudi Arabia sent by courier or post, the SFDA lists the clearance application, a prescription or medical report from the last six months, a copy of the patient's ID, the purchase invoice and the bill of lading.^[4]

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help families and treating doctors understand the route, prepare the documents the regulator or hospital asks for, arrange supply from the US once approval is in place, and keep everyone updated. We do not diagnose, prescribe or decide what a regulator approves.

We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.

Ask us about a medicine

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

What is a cold-chain medicine?

A medicine that must be kept within a set temperature range, often refrigerated or frozen, from manufacture until it is used.

How do I know the cold chain was not broken?

Ask for the temperature record from the data logger. WHO's good practices call for monitoring with calibrated instruments and review of transport temperature data on receipt.

What happens if the temperature went out of range?

WHO's good practices say the deviation must be reported to the supplier, distributor and recipient. The product should not be used until it has been assessed.

Can cold-chain medicines be cleared for personal use in Saudi Arabia?

Not if they are vaccines or need medical supervision; those are excluded from personal clearance and need a hospital route.

Sources for these answers: ^{[1, 2, 4]}

Sources

All sources were opened and checked on 17 October 2026. Rules and labels change, so the treating hospital or regulator confirms the current position before anything is filed.

World Health Organization: TRS 1025, Annex 7, Good storage and distribution practices for medical products (accessed 17 October 2026)
Reserve Meds: Answers to common access questions (sourced, reviewed 17 October 2026) (accessed 17 October 2026)
NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines (accessed 17 October 2026)
SFDA: Conditions and Requirements for the Clearance or Exportation of Individuals for Personal Use, version 1.1 (accessed 17 October 2026)
SFDA: Special Access Program (SAP) guidance, version 1.0 (accessed 17 October 2026)
US FDA: Approved Cellular and Gene Therapy Products (accessed 17 October 2026)

This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.